The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis

By M. Moasser. Oncogene, 2007

1,158 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

PI3K pathway alterations in cancer: variations on a theme (2008, positive): “Trastuzumab’s antitumor activity is thought to be conferred through receptor downregulation (Nagata et al., 2004). Two major drawbacks in the use of this antibody are frequent adverse side effects and the development of drug resistance. Nagata et al. (2004) and Berns et al.”
Human Epidermal Growth Factor Receptor 2 (HER2) in Cancers: Overexpression and Therapeutic Implications (2014, positive): “Moreover, HER2 dimerization promotes the mislocalization and rapid degradation of cell-cycle inhibitor p27Kip1 protein leading to cell-cycle progression [7, 10, 11].”
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. (2009, background): “77 Yes Yes Not given MMP13 expression correlates with HER2 and shorter OS 105 Bektas et al. (2008) [115] 250 Paraffin IHC 10.5 No Not done Not given Positive correlation between FOXM1 expression and HER2 status 106 Ludovini et al. (2008) [116] 256 Fresh, paraffin ELISA, FISH, IHC ELISA, 9; IHC/ FISH”